United Therapeutics Shareholders: Ownership Structure, Brands, and Acquisition History
Last updated: October 2026Ownership Structure
Ownership Analysis
Control at United Therapeutics is influential but not absolute. The April 2026 proxy gives founder and chief executive Martine Rothblatt 6.5% of the common stock, alongside BlackRock at 12.5%, Avoro at 6.8%, and Wellington at 5.8%. No party holds a majority, so the board remains formally accountable to all shareholders. Rothblatt’s executive position and long institutional memory nevertheless give her more practical strategic authority than her share count alone suggests. That combination has supported a distinctive corporate agenda: commercial pulmonary hypertension products fund an ambitious effort to develop transplantable organs. The structure has merit if directors preserve a clear boundary between the mature drug franchise and research projects whose economics remain unproven. June-quarter net income of $333 million and a $3.80 billion investment balance demonstrate financial capacity, but do not remove the need to rank projects. Directors should test clinical milestones, manufacturing readiness, and expected capital intensity before approving scale-up. Rothblatt’s 6.5% stake aligns her wealth with ordinary shareholders, yet tenure and founder status can make challenge less comfortable for other directors. A robust lead independent director, explicit succession plan, and post-investment reviews would help protect against that risk. Public benefit status can reinforce patient-centered goals, but it should not become a substitute for measuring returns on capital. Directors need independent scientific advice, a process for learning from failed experiments, and authority to redirect funds when data disappoint. The important governance question is not whether the founder has influence; it is whether that influence remains disciplined by clinical evidence, financial transparency, and a credible process for leadership transition. Board evaluation should include scenario planning for a future without Rothblatt in the chief executive role. An orderly transition would preserve the scientific mission while broadening management accountability.
Direct Owners
Institutional Shareholders
Shareholder Analysis
The shareholder base combines a substantial founder position with a diversified institutional register. BlackRock’s 12.5% proxy stake is the largest disclosed institutional block; Avoro Capital Advisors held 6.8%, Wellington 5.8%, and Rothblatt 6.5% as of April 10, 2026. The percentages describe reported beneficial ownership at that date and should not be treated as a synchronized live register. Institutions can shape compensation and board votes, but their portfolios are managed separately and the figures do not imply a voting coalition. Avoro’s specialist healthcare orientation may give it greater interest in clinical execution than index managers, while BlackRock and Wellington are likely to assess governance, capital returns, and long-term performance across a broader portfolio. For the board, those perspectives can be useful if engagement surfaces disagreement early rather than only at annual meetings. The business had $3.18 billion in 2025 revenue, and a large cash balance gives management discretion over repurchases, research, and capacity expansion. That discretion makes the quality of shareholder communication central. When Tyvaso formulations shift the product mix or a new indication alters the addressable market, the register needs to understand which changes are temporary and which alter future earnings power. Incentive plans should reward per-share value alongside revenue growth and scientific progress. A large repurchase authorization can be attractive when shares trade below intrinsic value, but it competes directly with research that could extend the company’s therapeutic reach. Shareholders should also monitor the founder’s board role and succession planning, given the company’s reliance on her vision. A healthy register can support long-term investment while still insisting on evidence, disciplined cash deployment, and clear accountability for clinical programs. The director slate should reflect capabilities in biopharma commercialization, clinical development, and highly regulated manufacturing. Shareholder support is more useful when the board can demonstrate those competencies.
Brands, Subsidiaries & Companies Owned
| Name | Type | Description |
|---|---|---|
| Tyvaso | Brand | Treprostinil therapy sold as dry powder inhaler and nebulized solution for pulmonary hypertension |
| Remodulin | Brand | Continuous infusion prostacyclin therapy for pulmonary arterial hypertension |
| Orenitram | Brand | Oral treprostinil therapy for pulmonary arterial hypertension |
| Unituxin | Brand | Antibody treatment for high-risk neuroblastoma |
| Adcirca | Brand | Tadalafil treatment for pulmonary arterial hypertension |
| Revivicor | Subsidiary | Xenotransplantation business developing genetically modified pig organs |
| Miromatrix | Subsidiary | Bioengineering platform for perfusable human organs and tissues |
Portfolio Analysis
Three established pulmonary therapies anchor United Therapeutics’ commercial portfolio.. Tyvaso, Remodulin, and Orenitram all address pulmonary arterial hypertension or related pulmonary vascular conditions through different routes of administration. That allows clinicians to select a therapy around patient needs and creates a commercial ecosystem in which clinical experience, specialty distribution, and manufacturing expertise reinforce one another. In Q2 2026, Tyvaso generated $452.6 million, but the total declined 4% year over year because nebulized Tyvaso fell 18%, partly offset by 4% growth in Tyvaso DPI. This split is strategically revealing: a product family can remain dominant while the formulation mix changes materially. Orenitram was nearly flat at $125.7 million, Remodulin fell 6% to $126.3 million, and Unituxin grew 12% to $65.2 million. The portfolio therefore contains both a large franchise navigating substitution and smaller products with different growth profiles. Adcirca contributes modest sales and broadens the treatment set, though it should not be confused with the core value driver. Revivicor and Miromatrix are different kinds of assets: their value lies in platform science, intellectual property, and clinical optionality rather than recurring brand revenue. These research businesses should remain distinct from commercial franchises until they generate repeatable sales. The portfolio’s strength is the ability to fund long-cycle innovation from established therapies; its vulnerability is dependence on a narrow disease area and the clinical, regulatory, and reimbursement outcomes attached to it. Management should show brand-level contribution, patient starts, retention, supply reliability, and the capital required to extend each product’s life. Growth in Tyvaso DPI is encouraging, but sustained value depends on proving that product transitions retain patients and open new populations rather than merely shifting sales between formulations. Specialty distribution and physician education create valuable customer relationships, but they also make channel execution central to the economics of each brand.
Market Share & Competitors
| Company | Market Share | Revenue | Key Strength |
|---|---|---|---|
| United Therapeutics ★ | 9.5% | $3.18B | Tyvaso franchise and established pulmonary hypertension portfolio |
| Gilead Sciences | 87.1% | $29.4B | Large commercial footprint in pulmonary and specialty medicines |
| Insmed | 3.3% | $1.1B | Rare respiratory disease focus and pipeline investment |
| Liquidia | 0.1% | $44M | Competing inhaled treprostinil program and focused development |
Competitive Analysis
Within pulmonary vascular medicine, United Therapeutics has an unusually focused commercial position.. The 2025 revenue base of $3.18 billion gives it substantial resources relative to smaller focused developers, and Q2 2026 Tyvaso sales of $452.6 million show the franchise’s weight. Yet leadership is not protected by scale alone. Liquidia’s inhaled treprostinil product, if successfully commercialized and adopted, challenges pricing, access, and patient retention; Insmed and other respiratory developers can compete for physician attention and clinical budgets. Large biopharma peers such as Gilead have broader resources but less direct comparability across their portfolios. For this reason, the chart percentages represent each selected company’s portion of the group’s combined reported revenue, not share of a single drug market. That scale measure helps distinguish incumbent resources from the economics of a specific indication. The more relevant competitive questions are whether Tyvaso DPI retains patients, whether new indications expand treatable populations, and how effectively the company supports specialty prescribers and payers. In Q2, DPI grew 4% while nebulized Tyvaso declined 18%, making execution on formulation migration a near-term priority. Patent duration, payer access, device performance, and emerging safety data will influence the franchise beyond headline revenue. The organ-transplant program offers differentiation outside drug competition, but it is not yet a commercial substitute for the current portfolio. Valuation should reflect durable patient economics and probability-adjusted pipeline cash flows, rather than a loose comparison with diversified pharmaceutical groups. A focused competitive moat exists, but it must be renewed through evidence and product execution. Management should also prepare for payer pressure, generic entry, physician familiarity with emerging therapies, and any change in the clinical standard of care. Strong data and reliable supply must translate into durable patient access if the franchise is to retain its commercial advantage.
Acquisitions
| Company Acquired | Deal Value | Year | Description |
|---|---|---|---|
| Miromatrix | undisclosed | 2023 | Acquired through a court-supervised sale to add perfusion-based organ engineering technology |
| IVIVA Medical | undisclosed | 2023 | Acquired to add bioengineered organ development capabilities |
| Revivicor | undisclosed | 2011 | Acquired xenotransplantation research assets and the genetically modified pig platform |
Acquisitions Analysis
A small set of targeted purchases extended United Therapeutics into organ engineering.. The 2011 purchase of Revivicor brought an established xenotransplantation program and genetically modified pig platform inside the company. Two 2023 transactions, Miromatrix and IVIVA Medical, added complementary work in perfusion-based organ engineering and bioengineered tissues. Miromatrix was acquired through a court-supervised sale for roughly $3 million, while the IVIVA terms were not disclosed. Those prices are small relative to a business that generated $3.18 billion of revenue in 2025, but purchase price understates the future cash burden: research, facilities, regulatory work, and clinical trials will drive the real investment. The sequence is strategically coherent because each asset relates to United Therapeutics’ stated ambition to address organ shortages. The challenge is that scientific adjacency does not guarantee commercial integration. A porcine organ platform, a perfusion-engineered organ, and a marketed pulmonary drug require different expertise, regulatory pathways, and manufacturing systems. Management should therefore report milestones by program and distinguish acquisition accounting from subsequent development spending. The new facilities announced for pathogen-free organ production create an additional test: capacity has value only when manufacturing processes, safety evidence, and transplant outcomes are validated. There is little evidence that these acquisitions were intended to generate near-term earnings synergies. Their value must instead be assessed through technical progress, intellectual-property position, and credible timelines toward human use. Further investment is justified when new data reduce uncertainty, not merely because prior spending has already occurred. Its cash reserve makes experimentation affordable; disciplined stop-go decisions will determine whether that flexibility creates a platform or an expensive collection of options. For investors, development expenditure after close will be more informative than the initial purchase price. Each research platform should have a clear evidence threshold before facilities or headcount expand.
Acquisition Timeline
Merger & Spin-off History
Merger & Spin-off Analysis
Before organ manufacturing entered the story, United Therapeutics was built around pulmonary hypertension medicine.. Founded in 1996 by Martine Rothblatt, United Therapeutics went public in 1997 and built an operating base around treatments for pulmonary hypertension. The later acquisition of Revivicor in 2011 marked a strategic departure: the company began investing in xenotransplantation as a possible answer to organ shortages. Miromatrix and IVIVA Medical, both acquired in 2023, brought separate but related capabilities in organ engineering. These transactions did not merge two large commercial sales forces, so conventional synergy measures such as headcount savings or cross-selling are not the right scorecard. The central question is whether the combined knowledge, patents, facilities, and research teams make human-organ manufacturing more feasible. Meanwhile, the established pharmaceutical business remains economically distinct and continues to fund development. In 2025 revenue rose 11% to $3.18 billion, while Q2 2026 revenue eased 2% year over year to $783.3 million. The strategy’s advantage is that external purchases can accelerate technical learning faster than building each capability internally. Its risk is organizational stretch: drug development and organ manufacturing have different regulatory, clinical, and operational clocks. Management reporting should identify program gates, intellectual-property ownership, and costs by research platform. If the xenotransplant path fails, the company should be able to limit further losses without destabilizing the marketed-drug franchise. A history of adjacent acquisitions supports a credible innovation thesis, but no deal should be considered successful until it produces clinical utility or a defensible commercial asset. The board should revisit these assumptions as clinical evidence matures, so each program receives capital in proportion to the progress it has actually made. Separate reporting for product revenue and research expenditure would make this strategy easier to judge. Without that separation, the mature franchise can obscure weak progress in newer science.
Ownership History
Ownership History Analysis
A founder’s family experience with pulmonary arterial hypertension shaped United Therapeutics from the outset.. Rothblatt founded the business after her daughter developed pulmonary arterial hypertension, making the corporate mission unusually personal and enduring. The 1997 public listing supplied capital to develop drugs and build commercial infrastructure, while leaving Rothblatt at the center of strategic leadership. Over time, institutional investors became major holders as the company grew into a multi-billion-dollar revenue business. The 2026 proxy’s 12.5% BlackRock, 6.8% Avoro, and 5.8% Wellington stakes illustrate that transition; Rothblatt still held 6.5%, enough to preserve a meaningful financial alignment without constituting majority ownership. The 2025 annual revenue of $3.18 billion and the company’s large investment balance are outcomes of the pharmaceutical franchise that grew from its founding focus. More recently, ownership capital has supported a second chapter in organ manufacturing through Revivicor, Miromatrix, and IVIVA. This shift changes what shareholders must evaluate. In the earlier phase, success could be judged largely through regulatory approvals and sales of pulmonary therapies. Today, the portfolio includes an uncertain, capital-intensive platform whose payoff may lie far in the future. That does not make the evolution irrational; it does make historical returns a poor proxy for the next phase’s risk. Organ-program updates need the same precision as drug economics, including spending, probabilities of success, and criteria for stopping a project. Founder influence can protect a long horizon, while institutional ownership broadens scrutiny. The strongest outcome would preserve the original patient-focused mission while ensuring that newer ambitions earn capital incrementally. Historical loyalty is valuable, but future reinvestment must stand on current evidence. The transition from founder-led drug development to a broader medical technology ambition will test whether the company can retain its original focus while building a second source of long-term value.
Ownership Explained
United Therapeutics is a publicly traded biotechnology company whose founder remains influential without holding a majority of its common shares. The 2026 proxy reports Martine Rothblatt beneficially owning 6.5%, while BlackRock held 12.5%, Avoro Capital Advisors 6.8%, and Wellington Management 5.8% at the proxy's April 10 record date. Those positions make the register concentrated enough for large holders to matter in director elections, but no investor has unilateral voting control. Rothblatt’s combined role as chair and chief executive supplies a durable strategic center; the board and public shareholders retain formal oversight rights. Its dual headquarters in Silver Spring and Research Triangle Park reflect the company’s Maryland roots and research and manufacturing presence in North Carolina. Its public benefit corporation status also places the mission of improving patients’ lives alongside shareholder returns in the corporate purpose. The operating structure is built around marketed medicines and a separate, earlier-stage organ manufacturing effort. Tyvaso, Remodulin, Orenitram, Unituxin, and Adcirca sit within the commercial pharmaceutical business, while Revivicor, Miromatrix, and IVIVA contribute to xenotransplantation and bioengineered organs. These research assets are owned by the public company and do not have independent public shareholders. Revenue was $3.18 billion in 2025, supported by established pulmonary hypertension drugs, while Q2 2026 revenue was $783.3 million. The founder’s continuing equity stake aligns her with ordinary holders, although founder influence also makes succession planning and independent board challenge important governance questions. The ownership arrangement combines public capital with a mission-led founder, and the critical test is whether long-duration research can be pursued without weakening returns from the profitable drug franchise. The founder’s influence is also visible in the company’s public benefit charter, which places patient outcomes within the stated corporate purpose alongside financial performance.
Patients and clinicians encounter a company whose most important decisions remain centralized at the parent level. United Therapeutics controls product strategy, clinical investment, manufacturing capacity, and the allocation of cash between marketed therapies and organ engineering. Rothblatt’s leadership gives the organization continuity across those choices, while the board oversees a public company accountable to outside shareholders. That arrangement can help sustain research programs that may take years to reach commercial use, but it also raises the value of transparent milestone reporting and credible succession planning. Employees work across a commercial drug business with established regulatory and physician relationships and experimental programs that may not produce near-term revenue. With $3.18 billion in 2025 revenue and $3.80 billion in cash and marketable investments at June 2026, United can fund both established products and research. Still, the use of that capital has competing claims: product launches, clinical trials, manufacturing, repurchases, and emerging xenotransplant facilities. For investors, no single outside shareholder can simply impose a strategic shift. Large institutions can influence proxy outcomes, while Rothblatt’s 6.5% holding and executive role give her substantial personal exposure to the long-term results. Customers and patients benefit when investment supports reliable supply, evidence generation, and broader access, rather than only financial engineering. That balance matters as the company expands Tyvaso into additional indications and tests whether bioengineered organs can move from research into clinical practice. A fair governance test is whether management separates proven cash generators from speculative science and reports budgets, timelines, and clinical evidence clearly enough for shareholders to evaluate progress. The structure offers patient capital, but patient capital still needs measurable accountability. Reliable availability matters as much as novel science for patients using continuous or inhaled therapy. Manufacturing interruptions could damage clinical confidence and complicate transitions between formulations.